Last updated on February 2018

An Investigational Immuno-therapy Trial of Nivolumab or Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum-doublet Chemotherapy Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)


Brief description of study

The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.

Clinical Study Identifier: NCT02477826

Contact Investigators or Research Sites near you

Start Over

Recruiting sites have contact information. ...

Local Institution
Yokohama-shi, Japan
4.63miles
  Connect »